For example, it has been shown that downregulation of AMPK activity is beneficial in both in vitro and in vivo models of familial amyotrophic lateral sclerosis, as well as in an in vivo mutant TDP-43 model of motor neuron disease (Lim et al., 2012). Here, PRKAA1 is linked to motor neuron disorder.